| JPM THEMATICS-GENETIC THERAPIES D (ACC) USD | RVI BIOTECNOLOGÍA | 79,403434 | 01/10/2026 | 23,61% | 29,40% | ** |
| JPM THEMATICS-GENETIC THERAPIES I2 (ACC) EUR (HEDGED) | RVI BIOTECNOLOGÍA | 120,830000 | 01/10/2026 | 19,88% | 37,90% | ** |
| JPM THEMATICS-GENETIC THERAPIES I2 (ACC) USD | RVI BIOTECNOLOGÍA | 89,953974 | 01/10/2026 | 25,10% | 35,73% | ** |
| JPM THEMATICS-GENETIC THERAPIES I (ACC) EUR | RVI BIOTECNOLOGÍA | 88,100000 | 01/10/2026 | 24,82% | 35,25% | ** |
| JPM THEMATICS-GENETIC THERAPIES I (ACC) EUR (HEDGED) | RVI BIOTECNOLOGÍA | 84,920000 | 01/10/2026 | 19,79% | 37,52% | ** |
| JPM TOTAL EMERGING MARKETS INCOME A (ACC) EUR | MIXTO AGRESIVO GLOBAL | 155,310000 | 01/10/2026 | 16,02% | 44,77% | ***** |
| JPM TOTAL EMERGING MARKETS INCOME A (ACC) USD | MIXTO AGRESIVO GLOBAL | 155,142503 | 01/10/2026 | 16,18% | 44,90% | ***** |
| JPM TOTAL EMERGING MARKETS INCOME A (DIST) EUR | MIXTO AGRESIVO GLOBAL | 109,360000 | 01/10/2026 | 13,26% | 33,25% | ** |
| JPM TOTAL EMERGING MARKETS INCOME A (DIV) EUR | MIXTO AGRESIVO GLOBAL | 109,190000 | 01/10/2026 | 11,25% | 22,22% | * |
| JPM TOTAL EMERGING MARKETS INCOME C (ACC) EUR | MIXTO AGRESIVO GLOBAL | 177,070000 | 01/10/2026 | 16,66% | 48,06% | ***** |